Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
2-Year U.S. Treasury Note Continuous Contract $103.762 0.000 0.00% 5-Year U.S. Treasury Note Continuous Contract $108.305 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $111.250 0.016 0.01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results